About: http://data.cimple.eu/news-article/a0ed50f507d8c77a68d728beba74d2a4ae1f6d06f9d6ef274cb3eab9

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/a0ed50f507d8c77a68d728beba74d2a4ae1f6d06f9d6ef274cb3eab9 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	Coronavirus vaccines using mRNA technology like Pfizer-BioNTech and Moderna appear able to "neutralise" the variant of Covid-19 behind India's outbreak, the EU's drug watchdog said Wednesday. There was "promising evidence" that such jabs could counter the B.1.617 variant of Covid-19, first found in India in October and now in dozens of countries around the world, the European Medicines Agency (EMA) said. "The data seems to be rather reassuring on the fact that at least the messenger RNA vaccines will be able to neutralise this variant, at least to an extent that will guarantee sufficient protection," Marco Cavaleri, the EMA's head of vaccine strategy, told a news conference. The Amsterdam-based regulator was "monitoring very closely" the data emerging about the Indian variant, he added. Cavaleri said the EMA also believed rival vaccines using viral vector technology would be effective but they were waiting for "real world data" from the use of a version of AstraZeneca's vaccine in India. "So far overall we are pretty confident overall that the vaccines generally will be covering this variant," the Italian said. The EU has currently authorised four vaccines: mRNA vaccines Pfizer/BioNTech and Moderna, and the viral vector vaccines AstraZeneca and Johnson & Johnson. Messenger RNA genetic technology trains the body to reproduce spike proteins, similar to that found on the coronavirus. When exposed to the real virus later, the body recognises the spike proteins and is able to fight them off. Viral vector vaccines like AstraZeneca and Johnson & Johnson use genetically-engineered version of a common-cold causing adenovirus as a "vector" to shuttle genetic instructions into human cells. The viral vector vaccines have however been dogged by reports of rare blood clots. The EMA also has four vaccines under "rolling review" Russia's Sputnik V, China's Sinovac, US firm Novavax and Germany's CureVac. dk/jz
schema:headline	EU agency says mRNA jabs 'promising' against India variant
schema:mentions	Novavax Italian language Adenoviridae Coagulation European Medicines Agency Johnson & Johnson Sputnik 1 Sinovac Biotech Nazi Germany AstraZeneca Messenger RNA European Union Russia Virus Pfizer India Vaccine China Coronavirus Coronavirus disease 2019 Viral vector Agencies of the European Union Euclidean vector CureVac
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2021-05-12 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	neutral sentiment
http://data.cimple...readability_score	80 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software